Pembrolizumab for Advanced Urothelial Carcinoma

Fei Liang¹, Ji Zhu^{1

2}

Affiliations

Comment

Fei Liang et al. N Engl J Med. 2017.

. 2017 Jun 8;376(23):2302.

doi: 10.1056/NEJMc1704612.

Fei Liang¹, Ji Zhu^{1

2}

No abstract available

Comment in

Pembrolizumab for Advanced Urothelial Carcinoma.
Bellmunt J, Bajorin DF. Bellmunt J, et al. N Engl J Med. 2017 Jun 8;376(23):2304. doi: 10.1056/NEJMc1704612. N Engl J Med. 2017. PMID: 28591526 No abstract available.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.